Best case scenario in my view (and limited knowledge of medical journals)...
1) Finish writing the paper. It would have been pretty much written already. The hypothesis, null hypothesis, methodology, and analysis will have been written early on. They will have to perform the analysis, plug in the results, and write the conclusion. Rough guess on my part... three weeks (late January).
2) Submit the paper for publication.
3) Complete the peer review. Here's where the "interim results" release will pay a dividend; there's probably a dozen peers out there all foaming at the mouth for the chance to see the final results! Rough guess on my part... three weeks (mid February).
4) Paper is accepted for publication, subject to editorial review, at some point in the future, when space is available.
5) Top line results announced in a letter in the next issue of the journal (March? issue), and also provided to Neurotech to support their FDA application.
- Forums
- ASX - By Stock
- NTI
- Ann: Clarification Statement
Ann: Clarification Statement, page-5
Featured News
Add NTI (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.7¢ |
Change
-0.002(2.90%) |
Mkt cap ! $64.55M |
Open | High | Low | Value | Volume |
6.9¢ | 6.9¢ | 6.7¢ | $7.631K | 113.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 577217 | 6.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.7¢ | 70967 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 589299 | 0.070 |
1 | 36231 | 0.069 |
5 | 240000 | 0.068 |
2 | 255000 | 0.067 |
3 | 262000 | 0.066 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 100000 | 1 |
0.074 | 40000 | 1 |
0.075 | 738582 | 2 |
0.076 | 90000 | 1 |
0.077 | 190000 | 3 |
Last trade - 10.29am 25/11/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online